{"id":"anastrozole-or-letrozole-or-exemestane","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hot flashes"},{"rate":"15-25","effect":"Arthralgia/joint pain"},{"rate":"10-20","effect":"Fatigue"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Osteoporosis/bone loss"},{"rate":"5-10","effect":"Vaginal dryness"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1444","moleculeType":"Small molecule","molecularWeight":"285.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aromatase inhibitors (anastrozole, letrozole, and exemestane) work by inhibiting the aromatase enzyme, which converts androgens to estrogen in postmenopausal women. By reducing circulating estrogen levels, these drugs suppress the growth of estrogen-dependent breast cancer cells. They are used as adjuvant therapy or for metastatic disease in hormone receptor-positive breast cancer.","oneSentence":"These aromatase inhibitors block the enzyme aromatase to reduce estrogen production in postmenopausal women with hormone receptor-positive breast cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:32.613Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer, adjuvant treatment in postmenopausal women"},{"name":"Hormone receptor-positive metastatic breast cancer in postmenopausal women"}]},"trialDetails":[{"nctId":"NCT06492616","phase":"PHASE3","title":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2024-09-27","conditions":"Breast Cancer","enrollment":4220},{"nctId":"NCT07391774","phase":"PHASE3","title":"Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-07","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8","enrollment":1978},{"nctId":"NCT00310180","phase":"PHASE3","title":"Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-04-07","conditions":"Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7","enrollment":10273},{"nctId":"NCT05307705","phase":"PHASE1","title":"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-05-11","conditions":"Breast Cancer","enrollment":193},{"nctId":"NCT01272037","phase":"PHASE3","title":"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-28","conditions":"Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma","enrollment":5018},{"nctId":"NCT05467891","phase":"PHASE2","title":"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Oana Danciu","startDate":"2022-09-13","conditions":"Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":200},{"nctId":"NCT07174336","phase":"PHASE3","title":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":920},{"nctId":"NCT07483307","phase":"PHASE2","title":"A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-13","conditions":"Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma","enrollment":176},{"nctId":"NCT00893061","phase":"PHASE3","title":"Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2009-03-16","conditions":"Breast Cancer","enrollment":44},{"nctId":"NCT06075953","phase":"PHASE2","title":"DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2024-02-17","conditions":"Ductal Carcinoma in Situ","enrollment":400},{"nctId":"NCT06016738","phase":"PHASE3","title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2023-11-16","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":510},{"nctId":"NCT06380751","phase":"PHASE3","title":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-01","conditions":"Advanced Breast Cancer","enrollment":500},{"nctId":"NCT06218303","phase":"PHASE1","title":"Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ","status":"RECRUITING","sponsor":"Finn, Olivera, PhD","startDate":"2024-02-07","conditions":"Ductal Carcinoma in Situ","enrollment":50},{"nctId":"NCT05700006","phase":"","title":"Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-07-25","conditions":"Breast Neoplasm Female, Arthralgia, Aging","enrollment":94},{"nctId":"NCT06671912","phase":"PHASE3","title":"Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-02-19","conditions":"Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8","enrollment":1156},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT04852887","phase":"PHASE3","title":"De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-06-07","conditions":"Stage I Breast Cancer","enrollment":1670},{"nctId":"NCT05827081","phase":"PHASE3","title":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-28","conditions":"Early Breast Cancer","enrollment":1400},{"nctId":"NCT05768139","phase":"PHASE1, PHASE2","title":"First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-04-17","conditions":"Breast Cancer, Solid Tumors, Adult","enrollment":720},{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma","enrollment":60},{"nctId":"NCT02767661","phase":"PHASE3","title":"Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2017-07-19","conditions":"Breast Cancer","enrollment":263},{"nctId":"NCT05774951","phase":"PHASE3","title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-31","conditions":"Breast Cancer, Early Breast Cancer","enrollment":4300},{"nctId":"NCT06507618","phase":"PHASE3","title":"Pre-Operative Window of ET to Inform RT Decisions (POWER II)","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2024-07-19","conditions":"Breast Cancer Female","enrollment":354},{"nctId":"NCT03179904","phase":"PHASE2","title":"TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-08-03","conditions":"Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8","enrollment":17},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT04961996","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-08-27","conditions":"Early Breast Cancer","enrollment":4170},{"nctId":"NCT06127979","phase":"NA","title":"A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-11-06","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT02947685","phase":"PHASE3","title":"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-06-21","conditions":"HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer","enrollment":518},{"nctId":"NCT07071038","phase":"PHASE2","title":"Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2025-10-17","conditions":"Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer","enrollment":62},{"nctId":"NCT06585969","phase":"PHASE3","title":"A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Danish Breast Cancer Cooperative Group","startDate":"2026-01-01","conditions":"Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B","enrollment":""},{"nctId":"NCT01674140","phase":"PHASE3","title":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2013-09-12","conditions":"Breast Cancer","enrollment":1939},{"nctId":"NCT07400523","phase":"PHASE3","title":"Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2026-02-10","conditions":"Breast Cancer","enrollment":446},{"nctId":"NCT05514054","phase":"PHASE3","title":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-10-04","conditions":"Breast Neoplasms","enrollment":8000},{"nctId":"NCT06311383","phase":"","title":"A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-10-09","conditions":"Breast Cancer","enrollment":2610},{"nctId":"NCT07024173","phase":"PHASE3","title":"A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2025-07-23","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":240},{"nctId":"NCT06970912","phase":"PHASE2","title":"ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-01","conditions":"Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer","enrollment":393},{"nctId":"NCT04584853","phase":"PHASE3","title":"PreOperative Endocrine Therapy for Individualised Care With Abemaciclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2020-12-23","conditions":"Breast Cancer Female","enrollment":123},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT04906395","phase":"PHASE3","title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05645536","phase":"PHASE3","title":"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study","status":"ENROLLING_BY_INVITATION","sponsor":"Tolmar Inc.","startDate":"2022-12-28","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT06369285","phase":"PHASE2","title":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Puma Biotechnology, Inc.","startDate":"2024-11-19","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer","enrollment":150},{"nctId":"NCT03079011","phase":"PHASE3","title":"PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2017-03-22","conditions":"Metastatic Breast Cancer","enrollment":1017},{"nctId":"NCT04569747","phase":"PHASE2","title":"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-01-11","conditions":"HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer","enrollment":375},{"nctId":"NCT04272801","phase":"PHASE2","title":"Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shayna Showalter, MD","startDate":"2020-04-07","conditions":"Breast Cancer Female","enrollment":84},{"nctId":"NCT06361940","phase":"PHASE2","title":"Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2024-09-30","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT07190443","phase":"PHASE3","title":"Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)","status":"RECRUITING","sponsor":"Japanese Foundation for Cancer Research","startDate":"2025-02-07","conditions":"Breast Cancer, Locoregional Recurrence, Abemaciclib","enrollment":290},{"nctId":"NCT07179939","phase":"PHASE2","title":"Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-10","conditions":"HER2-positive Breast Cancer","enrollment":288},{"nctId":"NCT03778931","phase":"PHASE3","title":"Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","status":"COMPLETED","sponsor":"Stemline Therapeutics, Inc.","startDate":"2019-05-10","conditions":"Breast Cancer","enrollment":478},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT07153757","phase":"PHASE3","title":"De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-01","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":2934},{"nctId":"NCT04134598","phase":"PHASE3","title":"ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2021-02-08","conditions":"Breast Cancer","enrollment":926},{"nctId":"NCT07101159","phase":"PHASE2","title":"Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-09","conditions":"Early Breast Cancer, Adjuvant Therapy, Hormone Receptor Positive / HER2-negative Breast Cancer","enrollment":200},{"nctId":"NCT02476786","phase":"PHASE2","title":"Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-01-17","conditions":"Breast Cancer, Cancer of Breast, Breast Neoplasms","enrollment":50},{"nctId":"NCT04767594","phase":"","title":"First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-10-27","conditions":"Breast Neoplasms","enrollment":1409},{"nctId":"NCT05952557","phase":"PHASE3","title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-10-05","conditions":"Breast Cancer, Early Breast Cancer","enrollment":5500},{"nctId":"NCT07005557","phase":"PHASE3","title":"Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-15","conditions":"Breast Cancer, Adjuvant Therapy","enrollment":1244},{"nctId":"NCT04188548","phase":"PHASE1","title":"A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-12-10","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":500},{"nctId":"NCT05472792","phase":"PHASE2","title":"Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-05-17","conditions":"Breast Cancer, Quality of Life","enrollment":90},{"nctId":"NCT03554044","phase":"PHASE1","title":"T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-02-05","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8","enrollment":20},{"nctId":"NCT05362760","phase":"PHASE4","title":"Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management","status":"RECRUITING","sponsor":"Prof. Wolfgang Janni","startDate":"2022-04-27","conditions":"Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT06957379","phase":"PHASE2","title":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-02-29","conditions":"HR+/HER2- Advanced/Metastatic Breast Cancer","enrollment":78},{"nctId":"NCT02040857","phase":"PHASE2","title":"Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-01","conditions":"Breast Cancer","enrollment":162},{"nctId":"NCT03219476","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-02-05","conditions":"Breast Cancer, Invasive Breast Cancer","enrollment":37},{"nctId":"NCT00265759","phase":"PHASE3","title":"Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2006-01","conditions":"Breast Cancer","enrollment":622},{"nctId":"NCT03820830","phase":"PHASE3","title":"Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-08-27","conditions":"Breast Cancer Recurrent","enrollment":405},{"nctId":"NCT01160211","phase":"PHASE3","title":"A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05-05","conditions":"Neoplasms, Breast","enrollment":369},{"nctId":"NCT03691493","phase":"PHASE2","title":"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-02-08","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative","enrollment":36},{"nctId":"NCT01897441","phase":"NA","title":"Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2013-06","conditions":"Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer","enrollment":31},{"nctId":"NCT05423730","phase":"NA","title":"Alcohol and Breast Cancer (ABC) Trial","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2022-09-01","conditions":"ER+ Breast Cancer, Breast Cancer, Aromatase Inhibitors","enrollment":23},{"nctId":"NCT01937052","phase":"","title":"Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2012-05-09","conditions":"Breast Cancer","enrollment":329},{"nctId":"NCT04985266","phase":"PHASE2","title":"A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2022-03-30","conditions":"ER+ Breast Cancer, HER2-negative Breast Cancer","enrollment":1100},{"nctId":"NCT06044623","phase":"PHASE3","title":"Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-01","conditions":"Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life","enrollment":495},{"nctId":"NCT05594095","phase":"PHASE2","title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-12-30","conditions":"Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor","enrollment":620},{"nctId":"NCT02188745","phase":"PHASE2","title":"ER Reactivation Therapy for Breast Cancer","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2016-03-11","conditions":"Metastatic Breast Cancer","enrollment":19},{"nctId":"NCT01619111","phase":"PHASE3","title":"DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs","status":"COMPLETED","sponsor":"Prof. Wolfgang Janni","startDate":"2012-02","conditions":"HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells","enrollment":105},{"nctId":"NCT02918084","phase":"PHASE3","title":"CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"2013-06","conditions":"Breast Cancer","enrollment":1000},{"nctId":"NCT02448420","phase":"PHASE2","title":"Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2015-07","conditions":"Metastatic Breast Cancer","enrollment":73},{"nctId":"NCT03272477","phase":"PHASE2","title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-10-05","conditions":"Breast Neoplasms","enrollment":257},{"nctId":"NCT04383275","phase":"PHASE2","title":"Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-08-23","conditions":"Breast Cancer","enrollment":356},{"nctId":"NCT05861271","phase":"PHASE2","title":"Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"Breast Cancer Stage I","enrollment":1008},{"nctId":"NCT02648477","phase":"PHASE2","title":"Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2016-03-28","conditions":"Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative","enrollment":30},{"nctId":"NCT05861830","phase":"PHASE3","title":"Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-05-15","conditions":"Advanced Breast Cancer","enrollment":80},{"nctId":"NCT05949541","phase":"PHASE2","title":"Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-07-26","conditions":"Breast Cancer, Advanced Breast Cancer","enrollment":265},{"nctId":"NCT01814397","phase":"","title":"Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-07","conditions":"Breast Cancer, Pain, Arthralgia","enrollment":50},{"nctId":"NCT06235931","phase":"NA","title":"A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2024-02-01","conditions":"Breast Neoplasms","enrollment":34},{"nctId":"NCT03312738","phase":"PHASE2","title":"A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-15","conditions":"Advanced Breast Cancer","enrollment":159},{"nctId":"NCT00641303","phase":"NA","title":"Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2008-05","conditions":"Anxiety Disorder, Breast Cancer, Depression","enrollment":51},{"nctId":"NCT05789771","phase":"","title":"Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.","status":"COMPLETED","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2022-04-01","conditions":"HR+/HER2- Breast Cancer, Metastatic Disease, Аdvanced Disease","enrollment":136},{"nctId":"NCT02894398","phase":"PHASE2","title":"Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2016-09-06","conditions":"Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","enrollment":388},{"nctId":"NCT01478477","phase":"NA","title":"Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2011-10-04","conditions":"Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer","enrollment":44},{"nctId":"NCT02753686","phase":"","title":"Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-03-15","conditions":"HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer","enrollment":440},{"nctId":"NCT05411380","phase":"PHASE2","title":"Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.","status":"UNKNOWN","sponsor":"wang shusen","startDate":"2022-10-03","conditions":"Breast Cancer","enrollment":73},{"nctId":"NCT03948568","phase":"PHASE4","title":"Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2019-09-17","conditions":"Early-stage Breast Cancer","enrollment":262},{"nctId":"NCT01989780","phase":"PHASE2","title":"Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2014-01","conditions":"Metastatic Breast Cancer","enrollment":160},{"nctId":"NCT00828854","phase":"PHASE2","title":"Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2008-10-01","conditions":"ER+ Breast Cancer","enrollment":27},{"nctId":"NCT03184090","phase":"PHASE2","title":"Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC","status":"COMPLETED","sponsor":"MedSIR","startDate":"2017-06-28","conditions":"Metastatic Breast Cancer","enrollment":33},{"nctId":"NCT03874325","phase":"PHASE2","title":"Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-04-26","conditions":"Breast Cancer, Hormone Receptor Positive Tumor","enrollment":17},{"nctId":"NCT03220178","phase":"PHASE4","title":"Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy","status":"TERMINATED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-07-24","conditions":"Breast Neoplasm","enrollment":532},{"nctId":"NCT02213042","phase":"PHASE2","title":"Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-10-24","conditions":"Neoplasms, Breast","enrollment":42},{"nctId":"NCT03078751","phase":"PHASE2","title":"Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-06-20","conditions":"Breast Cancer","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7828,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Clinical Practice","Experimental arm"],"phase":"phase_3","status":"active","brandName":"Anastrozole or Letrozole or Exemestane","genericName":"Anastrozole or Letrozole or Exemestane","companyName":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","companyId":"irccs-azienda-ospedaliera-universitaria-san-martino-ist-istituto-nazionale-per-l","modality":"Small molecule","firstApprovalDate":"","aiSummary":"These aromatase inhibitors block the enzyme aromatase to reduce estrogen production in postmenopausal women with hormone receptor-positive breast cancer. Used for Hormone receptor-positive breast cancer, adjuvant treatment in postmenopausal women, Hormone receptor-positive metastatic breast cancer in postmenopausal women.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}